Keeping Track: Approvals For Nuplazid, Cabometyx, Bevespi And More; Digital Aripiprazole Tablet Needs More Study
Executive Summary
The latest drug development news and highlights from our FDA Performance Tracker.
You may also be interested in...
Keeping Track: FDA's Review Actions Carry On During Shutdown
The latest drug development news and highlights from our US FDA Performance Tracker.
Can US FDA's Talk Therapy Cure What Ails Mental Health R&D?
By reducing regulatory uncertainty, US FDA’s Breakthrough Therapy Designation is helping adventurous sponsors try new trial designs and new mechanism in the long-stagnant field of psychiatry drug development.
Nuplazid Safety Review: Blast From the Past Or Preview Of Future Terrors?
Fueled by Congress, media attention, reevaluation of Acadia's Parkinson's drug feels like a scandal from pharma's primary care era – but is also a glimpse of what things might look like for industry if Democrats retake the House.